Femara tablets 2.5 mg, manufactured by Novartis Pharma, contain Letrozole and are indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women, with a standard of 2.5 mg per tablet (YJ code: 4291015F1026). This medication works by inhibiting aromatase, thereby reducing estrogen production.
Femara tablets 2.5 mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
